Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | BCKDK | O14874 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11262565 | 0.88 | KEAP1 (0.55) | KEAP1NFE2L2CYP2A6F7F3 | |
| SCHEMBL8290147 | 0.86 | KEAP1 (0.56) | KEAP1NFE2L2CYP2A6F7F3 | |
| SCHEMBL3180015 | 0.84 | KEAP1 (0.54) | KEAP1NFE2L2CYP2A6ALDH1A1CA2 | |
| SCHEMBL8290149 | 0.84 | CYP2A6 (0.56) | KEAP1NFE2L2CYP2A6CA2MAPT | |
| SCHEMBL7495653 | 0.80 | KEAP1 (0.54) | KEAP1NFE2L2CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL10901085 | 0.80 | NR4A2 (0.52) | KEAP1NFE2L2CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL8554891 | 0.80 | KEAP1 (0.54) | KEAP1NFE2L2CYP2A6SMN1; SMN2CA2 | |
| SCHEMBL6130731 | 0.80 | CA12 (0.52) | KEAP1NFE2L2ALDH1A1TSHRCA2 | |
| SCHEMBL30656160 | 0.80 | CA12 (0.52) | KEAP1NFE2L2ALDH1A1TSHRCA2 | |
| SCHEMBL2848485 | 0.79 | MAPT (0.47) | KEAP1NFE2L2ALDH1A1TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118756140-A | For CO2Laser direct drilling pretreatment additive, preparation method and application thereof | 昆山市板明电子科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-118756140-A | For CO2Laser direct drilling pretreatment additive, preparation method and application thereof | 昆山市板明电子科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3262026-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-9980929-B2 | Trifluoromethylpropanamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9869027-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20160230289-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9340759-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-0117675-B1 | BENZOFURAN AND BENZOTHIOPHENE-CARBOXYLIC-ACID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1986-07-23 | — | — | EP | disclosed |
| US-4548948-A | Anti-inflammatory and analgesic benzothiophene and benzafuran derivatives, compositions, and method of use therefor | BEECHAM GROUP P.L.C. (GB) | 1985-10-22 | — | — | US | disclosed |
| EP-0117675-A1 | Benzofuran and benzothiophene-carboxylic-acid derivatives | BEECHAM GROUP PLC (GB) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | PRMT7, GFRA3, PRMT5 | KEAP1 3839/4885NFE2L2 3986/4885CYP2A6 1008/4885 |
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | BAX, BAD, TMBIM6 | KEAP1 2493/4885NFE2L2 1083/4885CYP2A6 3706/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | KEAP1 2933/4885NFE2L2 1838/4885CYP2A6 3018/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | KEAP1 2933/4885NFE2L2 1838/4885CYP2A6 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.